Why It Matters

At stake in the November 20 Member Day hearing is control of the Judiciary Committee’s legislative and oversight agenda.

For Democrats: The hearing provides a platform to advance oversight of the Trump administration, particularly on prosecutorial independence and alleged rule-of-law violations. Rep. Jamie Raskin, the new Ranking Member, has made defending constitutional democracy central to Democratic priorities.

For Republicans: The hearing offers opportunities to advance their enforcement agenda, including stricter immigration policies and challenges to what they view as Democratic overreach.

Key issues at stake:

  • Rule of law and DOJ independence — Democrats aim to scrutinize alleged politicization of federal prosecution
  • Healthcare regulation — Navitus Health Solutions is lobbying on pharmacy benefit manager reform
  • Immigration enforcement — A defining partisan battleground within the committee’s jurisdiction
  • Criminal justice reform — Including sentencing, expungement, and youth prosecution
  • Patent protections — Veritaseum Inc. seeks a hearing platform on blockchain patent infringement

Broader Context

The House Judiciary Committee’s Member Day hearing arrives amid significant institutional tensions. Federal prosecutors have resigned en masse following a corruption case dismissal, raising Democratic concerns about Justice Department independence. Health care costs continue rising 3.3 percent year-over-year, fueling bipartisan interest in pharmacy benefit manager reform. Immigration enforcement remains a defining partisan battleground, with the Trump administration aggressively reshaping policy priorities.

The Agenda

The House Judiciary Committee’s Member Day hearing on November 20, 2025, will feature testimony from House members across the political spectrum.

Democratic participants include Ranking Member Jamie Raskin (D-MD-8), who has centered his role on defending democratic institutions. Rep. Jasmine Crockett (D-TX-30) brings experience as a public defender and civil rights attorney. Rep. Pramila Jayapal (D-WA-7) leads the Immigration Subcommittee.

Republican participation will likely include Rep. Laurel Lee (R-FL-15), who has engaged on prison reform initiatives.

Corporate interests are actively seeking platforms. Navitus Health Solutions LLC is lobbying on pharmacy benefit manager reform, while Veritaseum Inc. has persistently pursued opportunities to testify on blockchain patents.

Between The Lines

Ranking Member Jamie Raskin (D-MD-8) has declared his commitment to defending constitutional democracy and protecting the rule of law. He has used his position to oversee the Trump administration, including allegations of a \"Trump DOJ quid pro quo and cover-up\" related to former New York Mayor Eric Adams’ corruption case.

Key Democratic members positioning for oversight include Rep. Jerrold Nadler (D-NY-12), now leading the Antitrust Subcommittee, and Rep. Sydney Kamlager-Dove (D-CA-37), who has already joined Democrats in filing a resolution demanding Trump comply with the Constitution’s Emoluments Clause.

Competitive Landscape

Corporate interests are actively lobbying ahead of the hearing. Navitus Health Solutions LLC retained Faegre Drinker to lobby on PBM reform and pharmaceutical supply chain issues during Q2 2025.

Veritaseum Inc. has mounted a sustained campaign throughout 2025 via Rulon & White Governance Strategies, directly targeting House Judiciary Committee Chairman Jim Jordan seeking testimony opportunities on blockchain patent infringement issues.

The Bottom Line

The Member Day hearing on November 20 will reflect deep partisan divides over government accountability. Democratic leadership under Raskin is prioritizing Trump administration oversight and constitutional norms defense. Republicans are advancing immigration enforcement priorities. The hearing will preview legislative battles on criminal justice reform, immigration, healthcare regulation, and executive oversight that will dominate the committee’s remaining work in the 119th Congress.

For more detailed insights access Legis1. Request a demo today!

Spot something wrong? Report an issue with this article